Back
Open Access

SGLT2 inhibition ‒ early, first-line therapy across the spectrum of HF.

Session: SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice
Topic: Chronic Heart Failure
Speaker: Doctor D. Tomasoni (Brescia, IT)
Organised by Charité Friends & Sponsors Trust
Event: Heart Failure 2022

Congress Presentation

About the speaker

Doctor Daniela Tomasoni

Civil Hospital of Brescia, Brescia (Italy)
4 presentations
0 follower

5 more presentations in this session

Welcome and introduction.

Speaker: Professor S. Anker (Berlin, DE)

Access
Slides
Video
Thumbnail

Optimizing foundational therapies in HF ‒ can we do better?

Speaker: Professor A. Coats (Coventry, GB)

Access
Slides
Video
Thumbnail

SGLT2 inhibition in patients with HFpEF ‒ a case-based discussion.

Speaker: Professor G. Rosano (London, GB)

Access
Slides
Video
Thumbnail

Interactive panel discussion.

Speaker: Professor S. Anker (Berlin, DE) Professor A. Coats (Coventry, GB) Doctor D. Tomasoni (Brescia, IT) Professor G. Rosano (London, GB)

Access
Video
Thumbnail

Conclusion.

Speaker: Professor C. Lam (Singapore, SG)

Access
Video
Thumbnail

Access the full session

SGLT2 inhibition across the spectrum of heart failure: maximizing patient benefits in clinical practice

Speakers: Doctor D. Tomasoni, Professor S. Anker, Professor A. Coats, Professor G. Rosano, Professor S. Anker...
Access
Video
Thumbnail

About the event

Image

Heart Failure 2022

21 May - 24 May 2022

Sessions Presentations

Congress
logo Image

ESC 365 is supported by

logo Novo Nordisk
logo Bristol Myers Squibb